<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220326054351N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-08-30</date_registration>
      <primary_sponsor>Sabzevar University of Medical Sciences</primary_sponsor>
      <public_title>The prophylactic effect of theophylline on vancomycin-induced nephrotoxicity</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of theophylline on vancomycin-induced nephrotoxicity in children aged one month to 18 years with severe infection compared to vancomycin alone.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-08-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>34</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/62667</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: In this study, all children with severe infection, including meningitis and septicemia, who are treated with vancomycin are included.
In this method, we have two treatment groups, where T is considered as the group receiving theophylline and vancomycin, and C is considered as the group receiving vancomycin. Including blocks of four, we will have six modes that we use in the form of six cards with a replacement for random allocation. These six modes are as follows.
TTCC, TCTC, CTTC, CTCT, TCCT, CCTT
For a sample size of 34 to 9 times, we use the above cards with replacement, Blinding description: The method of blinding is single-blinding.
The researcher knows how to allocate drugs to the samples.
The laboratory expert does not know how to allocate the drugs to the samples.
The evaluator of laboratory results, is a person who is not aware of the treatment allocation.
The outcome is evaluated objectively, so there is no necessity  to blind the patient.</study_design>
      <phase>2-3</phase>
      <hc_freetext>nephrotoxicity.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:Patients are treated with vancomycin and theophylline. Vancomycin is prescribed at a dose of 15 mg/kg every eight hours from the first day of hospitalization. The duration of treatment is 7-10 days.(Vancomycin 500 vial manufactured by Dana Company under the brand name Vancomax.) Depending on which form of theophylline the child is able to take, syrup or tablets are chosen. Theophylline is prescribed daily at a dose of 5 mg/kg and lasts for three days.(Theochal-G syrup made by Alborz Drug Company or theophylline tablet E.R. 200 made by Razak Laboratory Company.). Intervention 2: Control group:pattients are only treated with vancomycin. Vancomycin is prescribed with dose of 15 mg/kg every eight hours from the first day of hospitalization. The duration of treatment is 7-10 days.(Vancomycin 500 vial manufactured by Dana Company under the brand name Vancomax.).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data can be anonymized after de-identifying individuals.

When:
The access period starts 6 months after the results are published

To whom:
Everyone is allowed to access the data.

Conditions:
In order to reanalyze and use the data in larger scale studies conducted by other researchers.

Where to obtain:
Dr.Aghil-allah Keykhosravi
drakeykhosravi@yahoo.com

How to obtain:
The request should be made through the provided email

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Aghil Keykhosravi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Heshmatieh hospital, Asad-abadi ST.</address>
        <city>Sabzevar</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9619795591</zip>
        <telephone>+98 51 4401 1600</telephone>
        <email>drakeykhosravi@yahoo.com</email>
        <affiliation>Sabzevar University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Aghil-allah Keykhosravi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Heshmatieh hospital, Asad-abadi ST.</address>
        <city>Sabzevar</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9619795591</zip>
        <telephone>+98 51 4401 1600</telephone>
        <email>drakeykhosravi@yahoo.com</email>
        <affiliation>Sabzevar University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with systemic infection treated with vancomycin
Patients one month to 18 years
Complete the informed consent form</inclusion_criteria>
      <agemin>1 month</agemin>
      <agemax>18 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients who are discharged from the hospital before three days.
Patients with unpredictable complications.
Patients with drug side effects.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:Patients are treated with vancomycin and theophylline. Vancomycin is prescribed at a dose of 15 mg/kg every eight hours from the first day of hospitalization. The duration of treatment is 7-10 days.(Vancomycin 500 vial manufactured by Dana Company under the brand name Vancomax.) Depending on which form of theophylline the child is able to take, syrup or tablets are chosen. Theophylline is prescribed daily at a dose of 5 mg/kg and lasts for three days.(Theochal-G syrup made by Alborz Drug Company or theophylline tablet E.R. 200 made by Razak Laboratory Company.)</i_keyword>
      <i_keyword>Control group:pattients are only treated with vancomycin. Vancomycin is prescribed with dose of 15 mg/kg every eight hours from the first day of hospitalization. The duration of treatment is 7-10 days.(Vancomycin 500 vial manufactured by Dana Company under the brand name Vancomax.)</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The percentage of people treated with vancomycin who develop microalbuminuria. Timepoint: Measurement of microalbuminuria at the beginning of the study and 72 hours after starting treatment with vancomycin. Method of measurement: Measurement of microalbuminuria in urine sample.The range is 30-300 mg per 24 hours.</prim_outcome>
      <prim_outcome>The percentage of people treated with vancomycin who experience an increase in urea and creatinineCommunity Verified icon. Timepoint: Measurement of urea and creatinine at the beginning of the study and 72 hours after starting vancomycin treatment. Method of measurement: Measurement of urea and creatinine in serum samples.Depending on the patients age, urea 20-30 mg/dL and creatinine 0.4-1 mg/dL.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Patient weight change. Timepoint: before treatment &amp; after three days from the start of treatment. Method of measurement: Measuring the patient's weight in kilograms with a digital scale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Sabzevar University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-01-02</approval_date>
        <contact_name>Ethics committee of Sabzevar University of Medical Sciences</contact_name>
        <contact_address>No. 196, Al-ahmad sq., Sabzevar Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
